Literature DB >> 3139346

Effect of lymphotoxin and tumor necrosis factor on endothelial and connective tissue cell growth and function.

M B Kahaleh1, E A Smith, Y Soma, E C LeRoy.   

Abstract

In an approach to understand the immune basis of human vascular and fibrotic disorders, the effects of recombinant human tumor necrosis factor alpha (rTNF) and lymphotoxin (rLT) on the in vitro growth and function of vascular and connective tissue cells were studied. Both rTNF and rLT stimulated fibroblast growth and protein, fibronectin, and collagen synthesis in dose-dependent fashion. In contrast, endothelial cell (EC) growth was inhibited by both cytokines; true EC cytotoxicity was seen at high concentrations (greater than or equal to 500 mu/ml). Addition of recombinant interferon-gamma markedly enhanced EC cytotoxicity while the growth factor beta-transforming growth factor reversed EC growth inhibition. Both rTNF and rLT stimulated factor VIII-Ag synthesis by EC. These contrasting effects of rTNF and rLT on fibroblast and endothelial cell growth and function in vitro are intriguing because they are the same contrasting effects observed in vivo in connective tissue and vascular disorders, raising the possibility of a role for these cytokines in these disorders. Study of the in vitro and in vivo mechanisms of these diverse effects may contribute to the understanding of certain human disorders characterized by endothelial injury and fibroblast activation leading to fibrosis.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3139346     DOI: 10.1016/0090-1229(88)90116-x

Source DB:  PubMed          Journal:  Clin Immunol Immunopathol        ISSN: 0090-1229


  11 in total

1.  Murine gammaherpesvirus-68 infection causes multi-organ fibrosis and alters leukocyte trafficking in interferon-gamma receptor knockout mice.

Authors:  B Ebrahimi; B M Dutia; D G Brownstein; A A Nash
Journal:  Am J Pathol       Date:  2001-06       Impact factor: 4.307

2.  Enhanced expression of the tumour necrosis factor/cachectin gene in peripheral blood mononuclear cells from patients with systemic vasculitis.

Authors:  Y Deguchi; N Shibata; S Kishimoto
Journal:  Clin Exp Immunol       Date:  1990-08       Impact factor: 4.330

3.  Production of tumor necrosis factor-alpha and lymphotoxin by cells of Hodgkin's neoplastic cell lines HDLM-1 and KM-H2.

Authors:  P L Hsu; S M Hsu
Journal:  Am J Pathol       Date:  1989-10       Impact factor: 4.307

Review 4.  Pharmacotherapy of Raynaud's phenomenon.

Authors:  J J Belch; M Ho
Journal:  Drugs       Date:  1996-11       Impact factor: 9.546

Review 5.  Clinical aspects of systemic sclerosis (scleroderma).

Authors:  R M Silver
Journal:  Ann Rheum Dis       Date:  1991-11       Impact factor: 19.103

6.  Fibroblast growth factor increases TNF alpha-mediated prostaglandin E2 production and TNF alpha receptor expression in human fibroblasts.

Authors:  M Candela; S C Barker; L R Ballou
Journal:  Mol Cell Biochem       Date:  1993-03-10       Impact factor: 3.396

7.  Tumor necrosis factor-alpha inhibits collagen synthesis in human and rat granulation tissue fibroblasts.

Authors:  K T Rapala; M O Vähä-Kreula; J J Heino; E I Vuorio; M K Laato
Journal:  Experientia       Date:  1996-01-16

8.  Tumor necrosis factor induces apoptosis (programmed cell death) in normal endothelial cells in vitro.

Authors:  B Robaye; R Mosselmans; W Fiers; J E Dumont; P Galand
Journal:  Am J Pathol       Date:  1991-02       Impact factor: 4.307

9.  NG-nitro-L-arginine methyl ester, an inhibitor of nitric oxide synthesis, ameliorates interleukin 2-induced capillary leakage and reduces tumour growth in adenocarcinoma-bearing mice.

Authors:  A Orucevic; P K Lala
Journal:  Br J Cancer       Date:  1996-01       Impact factor: 7.640

10.  Tumour necrosis factor-alpha mediates blood-brain barrier damage in HIV-1 infection of the central nervous system.

Authors:  M K Sharief; M Ciardi; E J Thompson; F Sorice; F Rossi; V Vullo; A Cirelli
Journal:  Mediators Inflamm       Date:  1992       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.